Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Cash (2019 - 2025)

IDEAYA Biosciences' Change in Cash history spans 7 years, with the latest figure at -$185.9 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 41.18% year-over-year to -$185.9 million; the TTM value through Dec 2025 reached $28.7 million, up 139.48%, while the annual FY2025 figure was $28.7 million, 139.48% up from the prior year.
  • Change in Cash for Q4 2025 was -$185.9 million at IDEAYA Biosciences, down from $184.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $217.2 million in Q3 2024 and bottomed at -$316.0 million in Q4 2024.
  • The 5-year median for Change in Cash is $1.9 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Change in Cash skyrocketed 4539.07% in 2021 before it crashed 6173.63% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$16.4 million in 2021, then tumbled by 103.41% to -$33.3 million in 2022, then surged by 115.61% to $5.2 million in 2023, then plummeted by 6173.63% to -$316.0 million in 2024, then soared by 41.18% to -$185.9 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Change in Cash are -$185.9 million (Q4 2025), $184.3 million (Q3 2025), and -$15.4 million (Q2 2025).